LV10918B - Method of use of azithromycin - Google Patents

Method of use of azithromycin Download PDF

Info

Publication number
LV10918B
LV10918B LVP-95-115A LV950115A LV10918B LV 10918 B LV10918 B LV 10918B LV 950115 A LV950115 A LV 950115A LV 10918 B LV10918 B LV 10918B
Authority
LV
Latvia
Prior art keywords
azithromycin
dosage form
food
oral
suspension
Prior art date
Application number
LVP-95-115A
Other languages
English (en)
Latvian (lv)
Other versions
LV10918A (lv
Inventor
William J Curatolo
George H Foulds
Hylar L Friedman
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22883977&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LV10918(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of LV10918A publication Critical patent/LV10918A/xx
Publication of LV10918B publication Critical patent/LV10918B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
LVP-95-115A 1994-04-29 1995-04-28 Method of use of azithromycin LV10918B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/235,069 US5605889A (en) 1994-04-29 1994-04-29 Method of administering azithromycin

Publications (2)

Publication Number Publication Date
LV10918A LV10918A (lv) 1995-12-20
LV10918B true LV10918B (en) 1996-06-20

Family

ID=22883977

Family Applications (1)

Application Number Title Priority Date Filing Date
LVP-95-115A LV10918B (en) 1994-04-29 1995-04-28 Method of use of azithromycin

Country Status (31)

Country Link
US (2) US5605889A (sh)
EP (1) EP0679400B1 (sh)
JP (3) JPH07300420A (sh)
KR (1) KR100354310B1 (sh)
CN (1) CN1088362C (sh)
AP (1) AP566A (sh)
AT (1) ATE183395T1 (sh)
AU (1) AU709328B2 (sh)
CA (1) CA2148071C (sh)
CO (1) CO4560547A1 (sh)
DE (1) DE69511451T2 (sh)
DK (1) DK0679400T3 (sh)
DZ (1) DZ1877A1 (sh)
ES (1) ES2136247T3 (sh)
FI (1) FI952060A (sh)
GR (1) GR3031290T3 (sh)
HU (1) HUT75244A (sh)
IL (1) IL113437A (sh)
LV (1) LV10918B (sh)
MA (1) MA23533A1 (sh)
NO (1) NO314386B1 (sh)
NZ (1) NZ548384A (sh)
OA (1) OA10151A (sh)
RU (1) RU2128998C1 (sh)
SI (1) SI0679400T1 (sh)
TN (1) TNSN95046A1 (sh)
TW (1) TW499311B (sh)
UA (1) UA34464C2 (sh)
UY (1) UY23935A1 (sh)
YU (1) YU49483B (sh)
ZA (1) ZA953439B (sh)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ292360B6 (cs) † 1994-05-06 2003-09-17 Pfizer Inc. Dávkovací forma s řízeným uvolňováním obsahující azithromycin a způsob její výroby
ES2079327B1 (es) * 1994-12-13 1996-08-01 Lilly Sa Formulaciones farmaceuticas de cefaclor.
PL186386B1 (pl) * 1995-02-08 2004-01-30 Yamanouchi Europ Bv Sposób wytwarzania granulatu zawierającego aktywny przy podawaniu drogą doustną antybiotyk beta-laktamowy oraz sposób wytwarzania szybko rozpadającejsię postaci dawkowania zawierającej aktywny przy podawaniu drogą doustną antybiotyk beta-laktamowy
US6383810B2 (en) * 1997-02-14 2002-05-07 Invitrogen Corporation Dry powder cells and cell culture reagents and methods of production thereof
US20060003447A1 (en) * 2003-12-30 2006-01-05 Richard Fike Dry powder cells and cell culture reagents and methods of production thereof
US20030212123A1 (en) * 1997-05-05 2003-11-13 Pfizer Inc. COX-2 selective carprofen for treating pain and inflammation in dogs
US6146655A (en) * 1997-08-29 2000-11-14 Softy-Flex Inc. Flexible intra-oral bandage and drug delivery system
US6129932A (en) * 1997-09-05 2000-10-10 Merck & Co., Inc. Compositions for inhibiting platelet aggregation
US6861411B1 (en) 1997-12-02 2005-03-01 Pfizer, Inc. Method of treating eye infections with azithromycin
US5955107A (en) * 1997-12-12 1999-09-21 Fmc Corporation Pharmaceutical suspension tablet compositions
US5914128A (en) * 1997-12-22 1999-06-22 Schering Corporation Orally administrable solid dosage form
US5916594A (en) * 1997-12-22 1999-06-29 Schering Corporation Process of making solid ribavirin dosage forms
CA2323849C (en) * 1997-12-22 2002-06-11 Schering Corporation Orally administrable solid ribavirin dosage forms and process for making them
US6239112B1 (en) * 1998-07-09 2001-05-29 Merial, Inc. Water miscible macrolide solutions
FR2793690B1 (fr) * 1999-03-30 2003-01-03 Cll Pharma Formulations pharmaceutiques en macrolides seuls ou associes a d'autres principes actifs et leur utilisation en therapeutique
BR0009437A (pt) * 1999-03-31 2002-01-15 Janssen Pharmaceutica Nv Amido pré-gelatinizado em uma formulação de liberação controlada
US6239113B1 (en) 1999-03-31 2001-05-29 Insite Vision, Incorporated Topical treatment or prevention of ocular infections
US7056893B2 (en) * 1999-03-31 2006-06-06 Insite Vision, Inc. Topical treatment for prevention of ocular infections
IL141438A0 (en) * 2000-02-23 2002-03-10 Pfizer Prod Inc Method of increasing the bioavailability and tissue penetration of azithromycin
US20030219405A1 (en) * 2002-01-16 2003-11-27 Yoshihiro Sokawa Oral administration of interferon-tau
DE60026718T2 (de) * 2000-07-25 2006-11-16 Laboratorio Silanes, S.A. De C.V. Einstufiges verfahren zur herstellung von 7,16-deoxy-2-aza-10-o-cladinosil-12-o-desosaminil-4,5-dihydroxi-6-ethyl-3,5,9,11,13,15-hexamethylbicycle(11.2.11)hexadeca-1(2)-en-8-ona undeine neue form von 9-desoxo-9a-methyl-9a-aza-9a-homoerythromycin a
EP1313749B1 (en) * 2000-08-23 2005-10-12 Wockhardt Limited Process for preparation of anhydrous azithromycin
WO2002036735A2 (en) * 2000-11-06 2002-05-10 Invitrogen Corporation Dry powder cells and cell culture reagents and methods of production thereof
US7119076B2 (en) * 2000-11-15 2006-10-10 Masao Sugamata Preventives or remedies for endometriosis or uterine myoma
HRP20010301A2 (en) * 2001-04-27 2001-12-31 Pliva D D New therapeutic indication for azithromycin in the treatment of non-infective inflammatory diseases
SI1390377T1 (sl) 2001-05-22 2006-06-30 Pfizer Prod Inc Nova kristalna oblika azitromicina
EA007618B1 (ru) * 2001-05-22 2006-12-29 Пфайзер Продактс Инк. Кристаллический полуторогидрат азитромицина, содержащая его фармацевтическая композиция и способ лечения на его основе
CZ2004232A3 (cs) * 2001-08-21 2005-10-12 Pfizer Products Inc. Jednorázová dávka azithromycinu
GB0123400D0 (en) 2001-09-28 2001-11-21 Novartis Ag Organic compounds
AU2006218279B2 (en) * 2001-09-28 2009-12-10 Novartis Ag Pharmaceutical compositions comprising colloidal silicon dioxide
EP1541134A3 (en) * 2001-10-18 2007-06-06 Teva Pharmaceutical Industries Limited Stabilized azithromycin compositions
US20080149521A9 (en) * 2001-10-18 2008-06-26 Michael Pesachovich Methods of stabilizing azithromycin
US6764997B2 (en) * 2001-10-18 2004-07-20 Teva Pharmaceutical Industries Ltd. Stabilized azithromycin compositions
CN1668282A (zh) * 2001-12-21 2005-09-14 辉瑞产品公司 可直接压制的阿齐霉素配方
CN1606433A (zh) * 2001-12-21 2005-04-13 辉瑞产品公司 阿齐霉素湿法制粒法
WO2003063838A1 (en) * 2002-02-01 2003-08-07 Pfizer Products Inc. Dry granulated formulations of azithromycin
WO2003074029A1 (en) * 2002-03-07 2003-09-12 Vectura Limited Fast melt multiparticulate formulations for oral delivery
US7101576B2 (en) * 2002-04-12 2006-09-05 Elan Pharma International Limited Nanoparticulate megestrol formulations
US20100226989A1 (en) * 2002-04-12 2010-09-09 Elan Pharma International, Limited Nanoparticulate megestrol formulations
US9101540B2 (en) 2002-04-12 2015-08-11 Alkermes Pharma Ireland Limited Nanoparticulate megestrol formulations
US20040105889A1 (en) * 2002-12-03 2004-06-03 Elan Pharma International Limited Low viscosity liquid dosage forms
GB0209265D0 (en) 2002-04-23 2002-06-05 Novartis Ag Organic compounds
BG748Y1 (bg) * 2002-07-02 2005-06-30 "BALKANFARMA-RAZGRAD" AD A{ô­{òM{}ö{ }{GC}{D A{DAAAAAAAAAAAAAAAAAAAAAAAAAA ЛЕКАРСТВЕНАБФОРМАБББББББББББББББББББББББББББББББББФЕДЙГБФЕХгЦдв@ЖЦЩФ@@@@@@@@@@@
WO2004074132A1 (en) * 2003-02-19 2004-09-02 Teva Pharmaceutical Industries Ltd. Methods of stabilizing azithromycin during storage by packaging in a gas impermeable container
US8507000B2 (en) * 2003-05-06 2013-08-13 Nostrum Pharmaceuticals, Inc. Controlled release formulation of erythromycin derivatives
US20050013835A1 (en) * 2003-07-15 2005-01-20 Pfizer Inc. Stable non-dihydrate azithromycin oral suspensions
DE602004019288D1 (de) * 2003-07-24 2009-03-19 Pliva Hrvatska D O O Schnellösliches azithromycin in einzeldosisform
TWI366442B (en) * 2003-07-30 2012-06-21 Novartis Ag Palatable ductile chewable veterinary composition
WO2005021056A1 (en) * 2003-08-21 2005-03-10 Cns, Inc. Effervescent delivery system
WO2005053639A2 (en) * 2003-12-04 2005-06-16 Pfizer Products Inc. Controlled release multiparticulates formed with dissolution enhancers
WO2005053652A1 (en) 2003-12-04 2005-06-16 Pfizer Products Inc. Multiparticulate crystalline drug compositions containing a poloxamer and a glyceride
US6984403B2 (en) * 2003-12-04 2006-01-10 Pfizer Inc. Azithromycin dosage forms with reduced side effects
CN1889931A (zh) * 2003-12-04 2007-01-03 辉瑞产品公司 利用挤压器制备优选含泊洛沙姆和甘油酯的多重粒子阿奇霉素组合物的喷雾－冻凝方法
BRPI0417348A (pt) * 2003-12-04 2007-03-13 Pfizer Prod Inc processo de gelatinização por spray com utilização de uma extrusora para preparação de composições de droga cristalina multiparticulada contendo preferencialmente um poloxámero e um glicerìdeo
UA78793C2 (en) * 2003-12-04 2007-04-25 Pfizer Prod Inc Oral dosage form of azitromycin with decreased side effects
MXPA06005913A (es) * 2003-12-04 2006-06-27 Pfizer Prod Inc Formas de dosificacion de multiparticulas de azitromicina por procedimientos basados en liquidos.
CA2547597A1 (en) * 2003-12-04 2005-06-16 Pfizer Products Inc. Multiparticulate compositions with improved stability
ES2308274T3 (es) * 2003-12-04 2008-12-01 Pfizer Products Inc. Procedimiento para fabricar multiparticulados farmaceuticos.
US20050131079A1 (en) * 2003-12-10 2005-06-16 Pujara Chetan P. Cefdinir oral suspension
US20050239735A1 (en) * 2003-12-30 2005-10-27 3M Innovative Properties Company Enhancement of immune responses
US20060116336A1 (en) * 2004-03-17 2006-06-01 American Pharmaceutical Partners, Inc. Lyophilized azithromycin formulation
US7468428B2 (en) * 2004-03-17 2008-12-23 App Pharmaceuticals, Llc Lyophilized azithromycin formulation
JP4713104B2 (ja) * 2004-08-04 2011-06-29 ファイザー株式会社 アジスロマイシン類を有効成分とする苦味が抑制された安定な組成物
US20060046970A1 (en) * 2004-08-31 2006-03-02 Insite Vision Incorporated Topical otic compositions and methods of topical treatment of prevention of otic infections
US20060182806A1 (en) * 2004-11-08 2006-08-17 Mintong Guo Extended-release propranolol composition
CA2595988A1 (en) * 2005-01-27 2006-08-03 Alembic Limited Extended release formulation of levetiracetam
US20060198895A1 (en) * 2005-03-07 2006-09-07 Kotliar Eleonora M Azithromycin powder for oral suspension compositions
EP1855693B1 (en) * 2005-03-07 2009-07-29 Teva Pharmaceutical Industries Ltd. Azithromycin powder for oral suspension compositions
DK1884242T3 (da) 2005-05-26 2013-05-06 Dainippon Sumitomo Pharma Co Farmaceutisk sammensætning omfattende lurasidon
CA2618977C (en) * 2005-08-10 2014-10-21 Shionogi & Co., Ltd. Orally disintegratable tablet
US20070191271A1 (en) * 2006-02-10 2007-08-16 Dow Pharmaceutical Sciences Method for stabilizing polypeptides lacking methionine
US8187659B2 (en) 2006-05-02 2012-05-29 Jerry Robertson Real Estate Llc Solid medicament dosage form consumption aid
US20080014271A1 (en) * 2006-07-13 2008-01-17 Ucb, S.A. Novel pharmaceutical compositions comprising levetiracetam
US8124123B2 (en) * 2007-09-05 2012-02-28 Dow Pharmaceutical Sciences, Inc. Controlled release azithromycin solid dosages forms
PT2554168T (pt) 2010-03-29 2018-02-28 Astellas Pharma Inc Composição farmacêutica de libertação controlada
WO2013088274A1 (en) 2011-12-14 2013-06-20 Wockhardt Limited Anhydrous amorphous azithromycin composition free of azithromycin dihydrate
AP2014007874A0 (en) 2012-02-06 2014-08-31 Merial Ltd Parasiticidal oral veterinary compositions comprising systemetically- acting active agents, methods and uses thereof
JP5941558B2 (ja) 2012-02-28 2016-06-29 株式会社ソウル製薬Ｓｅｏｕｌ Ｐｈａｒｍａ． Ｃｏ．， Ｌｔｄ． シルデナフィルを有効成分として含有し、且つ、苦味の隠蔽された高含量速溶フィルム
RU2498805C1 (ru) * 2012-07-23 2013-11-20 Открытое акционерное общество "Биосинтез" Твердая лекарственная форма азитромицина
CN104177457A (zh) * 2013-05-23 2014-12-03 长春海悦药业有限公司 一种阿奇霉素药物原料及其制剂和用途
US20150132382A1 (en) * 2013-11-11 2015-05-14 Forest Laboratories Holdings Ltd. Compositions and methods of treatment comprising fosfomycin disodium
RU2649834C1 (ru) * 2016-07-06 2018-04-04 Фармалидер С.А. Фармацевтическая композиция силденафила цитрата в форме суспензии для перорального применения

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI8110592A8 (en) * 1981-03-06 1996-06-30 Pliva Pharm & Chem Works Process for preparing of n-methyl-11-aza-10-deoxo-10-dihydroerythromycine a and derivatives thereof
US4382085A (en) * 1982-03-01 1983-05-03 Pfizer Inc. 4"-Epi erythromycin A and derivatives thereof as useful antibacterial agents
US4474768A (en) * 1982-07-19 1984-10-02 Pfizer Inc. N-Methyl 11-aza-10-deoxo-10-dihydro-erytromycin A, intermediates therefor
RU2066324C1 (ru) 1987-07-09 1996-09-10 Пфайзер Инк. Кристаллический дигидрат азитромицина и способ его получения
WO1989002271A1 (en) * 1987-09-10 1989-03-23 Pfizer Azithromycin and derivatives as antiprotozoal agents
SI9011409A (en) * 1990-07-18 1995-10-31 Pliva Pharm & Chem Works O-methyl azitromycin derivates, methods and intermediates for their preparation and methods for preparation of pharmaceuticals products which comprise them
EP0553353A1 (en) * 1990-10-15 1993-08-04 Taisho Pharmaceutical Co. Ltd 2'-modified erythromycin or derivative thereof
TW271400B (sh) 1992-07-30 1996-03-01 Pfizer
CA2173109A1 (en) 1993-10-01 1995-04-13 Kenneth Shyer Kornman Use of azithromycin for the treatment of adult periodontitis and topical compositions for this use
CZ292360B6 (cs) 1994-05-06 2003-09-17 Pfizer Inc. Dávkovací forma s řízeným uvolňováním obsahující azithromycin a způsob její výroby

Also Published As

Publication number Publication date
HU9501206D0 (en) 1995-06-28
TNSN95046A1 (fr) 1996-02-06
NO951630L (no) 1995-10-30
OA10151A (en) 1996-12-18
FI952060A (fi) 1995-10-30
CN1088362C (zh) 2002-07-31
DE69511451D1 (de) 1999-09-23
DZ1877A1 (fr) 2002-02-17
NO951630D0 (no) 1995-04-28
EP0679400B1 (en) 1999-08-18
US5605889A (en) 1997-02-25
CA2148071C (en) 2000-10-17
UA34464C2 (uk) 2001-03-15
LV10918A (lv) 1995-12-20
NZ548384A (en) 2008-04-30
ATE183395T1 (de) 1999-09-15
DK0679400T3 (da) 1999-12-06
NO314386B1 (no) 2003-03-17
ZA953439B (en) 1996-10-28
ES2136247T3 (es) 1999-11-16
JP2005015466A (ja) 2005-01-20
AP9500728A0 (en) 1995-04-30
AU1771195A (en) 1995-11-09
CO4560547A1 (es) 1998-02-10
TW499311B (en) 2002-08-21
AP566A (en) 1996-11-22
USRE39149E1 (en) 2006-06-27
IL113437A (en) 2001-04-30
CN1114879A (zh) 1996-01-17
KR100354310B1 (ko) 2002-12-26
CA2148071A1 (en) 1995-10-30
AU709328B2 (en) 1999-08-26
GR3031290T3 (en) 1999-12-31
IL113437A0 (en) 1995-07-31
RU2128998C1 (ru) 1999-04-20
SI0679400T1 (en) 1999-10-31
UY23935A1 (es) 1995-09-12
KR950028764A (ko) 1995-11-22
FI952060A0 (fi) 1995-04-28
MA23533A1 (fr) 1995-12-31
EP0679400A1 (en) 1995-11-02
YU27195A (sh) 1999-03-04
JPH07300420A (ja) 1995-11-14
JP2008231120A (ja) 2008-10-02
RU95106639A (ru) 1997-01-20
HUT75244A (en) 1997-05-28
DE69511451T2 (de) 1999-12-09
YU49483B (sh) 2006-08-17

Similar Documents

Publication Publication Date Title
US5605889A (en) Method of administering azithromycin
US5374659A (en) Aqueous pharmaceutical suspension for substantially water insoluble pharmaceutical actives
KR100493836B1 (ko) 옥스카르바제핀을 포함하는 제약 조성물
US8529952B2 (en) Pharmaceutical composition containing fenofibrate and method for the preparation thereof
KR960011772B1 (ko) 개선된 디데옥시 퓨린 뉴클레오사이드 경구 투여 제제
CZ332598A3 (cs) Pevná dávková forma cisapridu
WO2015200842A1 (en) Composition comprising metformin and a microbiome modulator
JP2511577B2 (ja) アルギン酸プロピレングリコ―ルエステルからなる徐放性製剤
AU744318B2 (en) Method of administering azithromycin
KR20190019061A (ko) 지연된 방출 경구 탐술로신 하이드로클로라이드
Jonkman Food interactions with once-a-day theophylline preparations: a review
KR20000050265A (ko) 아지스로마이신 경구 투여 제형을 포함하는 치료용 패키지
EP0835654A1 (en) Glucomannan-containing orally administered pharmaceutical preparations with sustained effect
EA042006B1 (ru) Композиция в качестве добавки кальция
CN107847496A (zh) 含有非索非那丁的软明胶胶囊